Difference between revisions of "Part:BBa K4165154"
 
Line 21: Line 21:
  
 
<html>
 
<html>
−
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm3.png" style="margin-left:200px;" alt="" width="300" /></p>
+
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/mm3.png" style="margin-left:200px;" alt="" width="500" /></p>
 
</html>
 
</html>
 +
 +
  
 
                             Figure 1.: Predicted 3D structure of Synthetic peptide MM3.
 
                             Figure 1.: Predicted 3D structure of Synthetic peptide MM3.

Latest revision as of 13:33, 13 October 2022


MM3

Tau binding peptide targeting the PHF seed of Tau

Usage and Biology

The amino acid sequence of the MM3 peptide is DPLKARHTSVWY. It is the L-enantiomeric peptide of MMD3 (BBa_K4165141). Its charge is +1, hydrophobicity is 41 %, molecular weight is 1472.65 Da. MM3 can reduce aggregates of full-length tau when mixed in ratio 1:10 and 1:5 and PHF* (VQIINK) but not PHF (VQIVYK).

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Dry Lab

Modeling

MM3 is modeled by Apptest, ITASSER and TrRosetta, best model obtained from trrosetta. 




                            Figure 1.: Predicted 3D structure of Synthetic peptide MM3.


Table 1: Quality assessment parameters of MM3 model.


References

1. Malhis, M. (2021). Selection and characterization of D-enantiomeric peptides for the investigation of options for therapy and diagnosis of Alzheimer's disease . University of Bayreuth (Germany).